Background. Fixed-dose combination scored dispersible stavudine, lamivudine, and nevirapine minitablets (Triomune Baby and Junior; Cipla Ltd) are simpler and cheaper than liquid formulations and have correct dose ratios for human immunodeficiency virus-infected children. However, they cannot be used for dose escalation (DE) of nevirapine.
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Strategies for Nevirapine Initiation in HIV-Infected Children Taking Pediatric Fixed-Dose Combination "Baby Pills" in Zambia: A Randomized Controlled Trial and administer. In contrast, fixed-dose combination (FDC) solid scored tablets, which can be dispersed or crushed and dosed according to weight-band tables, are easier for health workers to prescribe and carers to administer.
Until recently, adult FDC tablets (stavudine, lamivudine, and nevirapine) cut into parts were commonly used to treat HIVinfected children in resource-limited settings [4, 5] . However, lack of scoring, lack of dosing flexibility (as the child grows), and inappropriate ratios of the individual drugs for younger children because of varying drug metabolism with age results in inaccurate dosing-in particular, nevirapine underdosingwith concomitant risks of resistance emergence [5] . Cipla Ltd developed 2 triple-drug FDC tablets with the correct drug ratios for children, Triomune Baby and Triomune Junior (6 and 12 mg of stavudine, respectively; 30 and 60 mg of lamivudine, respectively; and 50 and 100 mg of nevirapine, respectively). These are small scored dispersible tablets providing appropriate pharmacokinetic levels for children when given in accordance with World Health Organization (WHO)-recommended weight-band dosing tables [6] . However, to escalate the nevirapine dose as recommended, common practice in Zambia has been to initiate ART using 3 syrups, changing to triple FDC tablets 2 weeks later.
Nevirapine toxicity has been reported to be relatively uncommon among children, both in the United States [7, 8] and Africa, where a Ugandan study found few problems using fulldose (FD) adult Triomune tablets in children from ART initiation [9] . However, there are few prospective pediatric data on nevirapine toxicity, and no randomized trials have evaluated the safety of starting with FD nevirapine immediately in either adults or children.
METHODS
CHAPAS-1 (Children with HIV in Africa-Pharmacokinetics and Adherence of Simple Antiretroviral Regimens) was an open, randomized trial conducted at the University Teaching Hospital, Lusaka, Zambia (ISRCTN31084535). Children aged 3 months to 14 years with confirmed HIV infection and no history of ART (including for prevention of mother-to-child transmission) who fulfilled WHO 2006 guidelines for ART initiation [10] were enrolled. Children were randomized to initiate ART with FD triple-drug FDC Triomune Baby or Junior twice daily for 2 weeks (the FD group) or to Triomune Baby or Junior once daily for the first 2 weeks, together with once-daily Lamivir-S (dual-drug Baby [6 mg of stavudine and 30 mg of lamivudine] or Junior [twice the dose for Baby] FDC; the dose escalation [DE] group). After 2 weeks, DE children discontinued Lamivir-S and continued with Triomune Baby or Junior twice daily. Lamivir-S Baby and Junior were produced by Cipla for CHAPAS-1.
Randomization was in a 1:1 ratio, stratified by age (3 months to 6 years and 7-14 years). A computer-generated sequential randomization list, constructed using variable block size, was prepared in advance by the trial statistician and incorporated securely into the trial database. The list was fully concealed until allocation, after eligibility had been established and a randomization request made to data management staff.
All children (regardless of randomized group) were seen by a nurse 2 and 4 weeks after randomization (ART initiation) and then every 4 weeks until the last child reached 48 weeks (October 2008). At each visit, children were weighed and measured, any adverse events (AEs) or new WHO events were recorded, and additional ART was prescribed. Children were routinely seen by a doctor at weeks 2, 4, 8, and 12 and then every 12 weeks. Doctors conducted a clinical examination, and blood samples were obtained for hematology, biochemistry, and lymphocyte subsets and plasma storage.
The primary outcome was grade 3 or 4 AEs definitely/probably or uncertainly related to nevirapine. Secondary outcomes were grade 2-4 AEs definitely/probably related to nevirapine; adherence, determined on the basis of questionnaires and pill counts; mortality; disease progression, determined on the basis of new WHO stage 3 or 4 events; viral load, measured retrospectively in stored postbaseline samples by means of the Roche Amplicor 1.5 test (lower limit of detection, 250 copies/mL [because of small volumes requiring dilution]); growth and changes in CD4 cell count and percentage from baseline; and the pharmacokinetic parameters of nevirapine, lamivudine, and stavudine [6] . All WHO 3 or 4 events, deaths, and grade 3 or 4 AEs were reviewed without knowledge of randomized group by the End Point Review Committee, which comprised the United Kingdom principal investigator (D.M.G.) and a clinician from the University Teaching Hospital (C. Kankasa) who was not involved in CHAPAS-1 clinical care.
The sample size of 200 children provided 80% power to detect a 15% absolute increase in nevirapine-related grade 3 or 4 AEs, from 10% in the DE group to 25% in the FD group (1-sided ) . Fifteen percent was the minimum increase a p .05 in toxicity judged to be clinically relevant to detect: we could not find any data on expected FD rates in adults or children. When enrollment was nearly complete, few children had been entered into the lowest 3-6-kg dosing band. To enable pharmacokinetic analysis in this subgroup, the sample size was increased to 210 and recruitment was limited to very young children to be followed only to October 2008 [11] . An independent data-monitoring committee reviewed the study twice, in February 2007 and June 2008, and on both occasions recommending continuation.
All analyses were done on an intention-to-treat basis. Comparison of event rates between randomized groups used per- son-time analysis, comparing rate ratios by exact 2-sided significance tests. Mortality analyses used time-to-event survival methods, comparing hazard ratios (HRs) by log-rank tests. Predictors of nevirapine reactions were investigated by multivariable logistic regression, using backward elimination with Akaike's information criterion. Global comparisons between randomized groups in changes in adherence, CD4 cell count and percentage, viral load, and anthropometric parameters to 96 weeks were analyzed using generalized estimating equations. Weight-for-age and height-for-age z scores were determined using the British 1990 reference [12] , because it covers the full age range of CHAPAS-1 children. Stata software, version 10 (StataCorp), was used in all analyses.
RESULTS
Between February 2006 and October 2007, 204 children were randomized. An additional 8 children weighing 3-6 kg and !2 years old were randomized to June 2008. One child was randomized in error (mistakenly considered to not meet WHO criteria for ART and not prescribed drugs or followed up) and was excluded from analysis. Thus, the intention-to-treat analyses included 211 children, 105 in the FD group and 106 in the DE group ( Figure 1 ).
Baseline characteristics were reasonably balanced between randomized groups (Table 1 ). The median age at ART initiation was 5 years (35% were !3 years old). Severe wasting and/or stunting were common, with 150% children having weightfor-age and height-for-age z scores below Ϫ3 and none having scores above zero. Ninety-nine percent had WHO stage 3 or 4 HIV disease, and 58% had a CD4 cell percentage !15%.
The median duration of follow-up to October 2008 was 92 weeks (interquartile range [IQR], 68-116 weeks). Seventeen children (8%) were not known to have died and were not seen during October 2008 (trial closure); their median duration of follow-up was 25 weeks (IQR, 12-44 weeks), with 2 of 17 not seen after randomization. Changing residence was the most common reason for losses to follow-up.
All children initiated ART within 1 day of randomization. One hundred DE children (94%) completed DE after a median of 14 days (IQR, 14-15 days; range, 12-35 days); the remaining 6 either died (3), were lost to follow-up (1), or substituted efavirenz for nevirapine within 14 days (1 rash and 1 tuberculosis cotreatment). In total, nevirapine was interrupted 32 times in 28 children, 19 (18%) in the FD group and 9 (8%) in the DE group (exact ). Thirteen substitutions (8 in P p .04 FD and 5 in DE) with efavirenz or abacavir were due to tuberculosis cotreatment, 13 changes (11 in FD and 2 in DE) were for AEs (temporary nevirapine interruption [11] or efa- Figure 2A ). All were P p .74 asymptomatic laboratory AEs, and all children continued nevirapine therapy without interruption or dose change. Most frequent events were elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels (11 in Elevation in liver enzyme level (AST or ALT) 13 12 Elevation in alkaline phosphatase level 1 0 ( ) or 2 ( ) rash was associated with transient grade n p 2 n p 1 3 elevated AST or ALT levels. Of the 15 children who developed rash, 3 (FD) continued FD nevirapine; 9 (8 in FD and 1 in DE) temporarily stopped nevirapine (by substituting Lamivir-S for a median of 8 days [range, 6-8 days]) and then successfully escalated the dose of nevirapine; 1 (FD), in whom rash returned after interruption and DE, substituted efavirenz for nevirapine; and 2 (1 in FD and 1 in DE) substituted efavirenz without retrying half-dose Triomune. All but 2 children (both FD) were managed as outpatients; 2 were admitted for observation (1 early during the trial and 1 during successful continuation of FD nevirapine). In multivariable regression models, nevirapine reactions (either rash alone [15/211; 7%] or rash or definitely/ probably nevirapine-related grade 3 or 4 elevated AST or ALT level [21/211; 10%]) were significantly more common both in older children and in those with higher CD4 cell counts for age ( Table 3 ). The risk was also nonsignificantly higher for girls.
HIV-related events. Twenty-two (10%) children died (6.9 and 5.7 deaths per 100 child-years in the FD and DE groups, respectively; FD:DE HR, 1.19; 95% CI, 0.51-2.75; ). No P p .7 deaths were judged to be drug related, and most occurred soon after randomization: 6 (1 in FD and 5 in DE) during the first 4 weeks and 6 more (4 in FD and 2 in DE) during weeks 4-12. The cause of death was most frequently diarrhoea ( ) n p 7 or serious lung disease ( ); most children who died had n p 3 advanced HIV infection and very low weight-for-age z scores (mean, Ϫ4.5) at ART initiation.
Five new or recurrent WHO stage 4 events and 19 stage 3 events occurred in 21 children. WHO stage 3 events were mostly pulmonary tuberculosis ( ) or oral candidiasis ( ); n p 10 n p 8 3 stage 4 events were extrapulmonary tuberculosis. Overall, 40 children had a WHO stage 3 or 4 event and/or died (19%)-13.9 and 11.1 events per 100 child-years in the FD and DE groups, respectively (FD:DE IRR, 1.26; 95% CI, 0.64-2.49;
). P p .5
There were no significant differences between randomized groups for changes in weight-for-age z scores, height-for-age z scores, and absolute CD4 cell counts or CD4 cell percentages to 96 weeks ( , , , and , respec-P p .06 P p .66 P p . 16 P p .99 tively). Increases in weight-for-age z scores occurred sooner and were larger than increases in height-for-age z scores; however, although increases in weight-for-age z scores slowed between 48-96 weeks, increases in height-for-age z scores continued at a similar rate. At 96 weeks, weight-for-age z scores had increased by a mean of +1.7 and +1.4 in the FD and DE groups, respectively; height-for-age z scores increased by +0.9 and +0.7, respectively; CD4 cell counts increased by +518 and +554 cells/mL, respectively; and CD4 cell percentage increased by +17.3% and +17.3%, respectively. Viral load was !250 copies/mL in 78% ( ) at 48 weeks and in 75% ( ) at n p 116 n p 66 96 weeks, with no differences between groups (74% in FD and 82% in DE at 48 weeks [ ]; 78% in FD and 73% in DE P p .2 at 96 weeks [ ]). Viral load was 11000 copies/mL in 17% P p .6 ( ) and 20% ( ), respectively. n p 25 n p 18
DISCUSSION
The CHAPAS-1 trial was designed to evaluate dosing strategies for the pediatric antiretroviral FDCs Triomune Baby and Junior, which contain different ratios of stavudine, lamivudine, and nevirapine relative to the adult FDC and result in appropriate pharmacokinetic parameters in Zambian children [6, 11] . The US Food and Drug Administration and WHO approved this pediatric FDC across weight bands down to 3 kg in 2007.
Here, we present a comparison of the safety and longer-term clinical and immunological outcomes between starting Triomune Baby/Junior at FD versus the recommended 14-day nevirapine DE, using a combination of dual-and triple-drug FDCs. There are few prospective data documenting adverse reactions to nevirapine in African children, and no randomized trials comparing DE and FD strategies in adults or children have been conducted. The rationale for the trial was that nevirapine DE in children requires additional drug formula- 
NOTE.
Nonlinear associations with continuous variables were investigated using fractional polynomials, but none were found (ie, there was no evidence of any threshold at which risk increased or decreased more quickly). ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; DE, dose escalation; FD, full dose; OR, odds ratio.
a Univariable results were also adjusted for FD vs DE (data not shown). b Multivariable models were based on backward selection using Akaike's information criterion.
tions that for syrups are difficult to procure and complex to administer: the dual pediatric lamivudine-stavudine FDC was not available when the trial commenced. Guidelines mandating nevirapine DE may therefore be a significant barrier to ART initiation in children. In addition, early adverse reactions to nevirapine have been reported to be less frequent among children [7, 8] than adults [13, 14] , suggesting that DE might be less important in children. Thus, if starting with FD Triomune Baby or Junior resulted in few additional AEs, there could be substantial benefits to program planners from not having to procure extra formulations for nevirapine DE. The CHAPAS-1 DE strategy was once-daily Triomune Baby or Junior in the morning given with once-daily Lamivir-S Baby or Junior in the evening (lamivudine-stavudine in the same doses as Triomune Baby and Junior), manufactured for the trial by Cipla as scored dispersible tablets. This DE strategy is considerably less costly than separate syrups for each drug in the FDC and is simpler for caregivers and dispensing providers, as well as procurers. One alternative strategy considered was to give a half dose of the whole FDC (ie, half-dose lamivudinestavudine as well as half-dose nevirapine) for the first 2 weeks. However, the risk of early resistance development from initial lamivudine underdosing was considered greater than the risk of nevirapine toxicity from starting a FD FDC, especially in young children [15] . We found the dual or triple FDC DE approach was very acceptable; the color and shape of the tablets are distinct, and at the 2 week visit nurse questionnaires identified very few wrong doses (data not shown). In addition, at trial exit carers and older children reported by questionnaire that it was easy to initiate ART using these drug formulations.
The CHAPAS-1 primary end point was grade 3 or 4 clinical or laboratory AEs (according to reference toxicity tables) with a definite/probable or uncertain relationship to nevirapine. Similar proportions of children had primary end points in each randomized group, but clinical relevance is limited as most were single grade 3 elevations in liver enzyme or bilirubin levels, which were asymptomatic and resolved spontaneously without stopping nevirapine or changing the dose. The elevated liver enzyme levels generally occurred soon after ART initiation, and there was little overlap with nevirapine-associated rash. Our results add to those of the DART trial, which showed no difference in ART-modifying AEs among African adults receiving routine versus clinically driven biochemistry monitoring, including among those receiving nevirapine [16, 17] . The results of both trials suggest that routine liver function tests are not required after nevirapine initiation in resource-limited settings. The grade 3 elevations in bilirubin levels are unexplained and occurred throughout the trial, if anything more frequently in the DE group; although investigated, laboratory error cannot be excluded. However, we did observe significantly more grade 1 or 2 rashes in the FD group. Management varied, but most children temporarily interrupted nevirapine and subsequently restarted successfully with DE. Only 3 substituted efavirenz: 1 in the FD group early during the trial, 1 in the DE group, and the only child in the FD group who experienced a recurrent rash on rechallenge with nevirapine DE. Of note, only 1 child was "treated through" the rash, and it is possible that more could have been managed with this approach. Only 2 children with rashes were admitted to the hospital: 1 early during the trial, and the child who was treated though; however, both were admitted for observation, not because of rash severity. Clini-cians were not masked to randomized group, which introduces the possibility of ascertainment bias; however, a small, nonsignificant increase in nevirapine concentration was observed in children who developed rash (data not shown). We are confident that we did not miss any serious reactions among children early during the trial, when mortality was high; furthermore, only 1 child died during the first month of ART in the FD group, compared with 4 deaths in the DE group.
A nonsignificantly higher risk of nevirapine rash was observed among females, as has been reported in adults [18] . Older children and those with higher CD4 cell counts were also more likely to develop nevirapine rash, in keeping with the more immature immune systems of younger children and with results observed among adults [19, 20] . Although we observed different rates of grade 1 or 2 rashes in the CHAPAS-1 DE and FD groups, our findings broadly agree with previous results showing lower clinical event rates among children than adults [7, 8, 13, 14, 21] . Hepatotoxicity has also been reported more frequently among adults than children in previous studies [7, 8, 20] ; in CHAPAS-1, although rates of single elevated liver enzyme levels differed between randomized groups, no child had confirmed (second) elevated levels of liver enzymes. DE using Lamivir-S does not increase drug costs, compared with FD initiation using Triomune Baby and Junior. However, with DE using syrups the cost of preventing 1 grade 1 or 2 rash is approximately $40. An alternative way to escalate the dose (not evaluated in this trial) is to use cut parts of unscored adult lamivudine-stavudine tablets for the first 2 weeks of ART, when inaccuracies dividing tablets may be less important.
In CHAPAS-1, more than half the deaths occurred during the first 3 months of ART, most commonly due to diarrhoea and pneumonia. Similar findings have been reported in pediatric cohorts in resource-limited settings [22, 23] , including Zambia [24] . There were no differences between randomized groups in any measure of HIV disease, including weight or height gains, CD4 cell percentage, and viral load response to ART. As reported elsewhere, CD4 cell response is good in children, and HIV RNA suppression at 48 weeks was comparable to data from previously untreated children in well-resourced [25, 26] and resource-limited [27] countries. These data boost our confidence that triple FDC generic "minipills" for children are appropriate for African children.
In conclusion, we have shown that rash occurred more frequently among children starting nevirapine at FD, although 88% had no clinical toxicity. Elevated AST or ALT values were unconfirmed, transient, and resolved spontaneously, suggesting that routine laboratory monitoring has limited value. Wherever possible, dual pediatric stavudine-lamivudine minitablets should be made available for safe and simple DE, which is more cost-effective than syrups. If dual-drug adult or pediatric solid formulations are not available and FD Triomune Baby or Junior tablets are used, caregivers should be aware of the timing of rash. For children developing rash, the options are to treat through with careful clinical observation or to reduce to halfdose Triomune during reescalation, given that we observed few recurrences of rash with DE after rash following initiation with FD nevirapine.
